Regulatory Daily Summary: What Happened on October 14, 2026

MHRA targets shorter reviews and new rules for AI health tools

The Medicines and Healthcare products Regulatory Agency (MHRA) published a strategy for UK oversight of medicines, medical devices, clinical research, and AI-enabled health technologies through 2030.1 The agency plans to cut the turnaround for higher-tier scientific advice from 90 days to 45, and set a 14-day initial assessment target for qualifying Phase 1 trials.1

The MHRA plans to use more real-world data and AI analysis to identify possible safety issues sooner, establish a center for AI and digital health, and develop an adaptive framework for AI medical devices.1 It plans to publish an action plan on AI in medicines development in 2027 and introduce a Women's Health Plan during the year.1 The strategy also aims to increase diversity in clinical studies, improve patient-centered regulation, and support quicker access to safe treatments, according to the agency.1

Also published

• Sanofi escapes fine in EU mismarketing case pharmaphorum
• FDA new drug approvals in Q3 2026 Nature Reviews Drug Discovery